Segal Cancer Centre
Message from the Director
Oncology Interdisciplinary Teams
New Referrals
Cancer Treatment Unit
Oncology Nursing
Oncology Pharmacy
Radiation Oncology
Psychosocial Oncology Program
Hope & Cope
Cancer Prevention Center
Cancer Nutrition Rehabilitation Center
Oncology and Aging Program
Palliative Care
Adolescent and Young Adult Oncology Program
Education and Training
Molecular Pathology
Peter Brojde Lung Cancer Centre
Segal Cancer Centre News
Handling of Body Fluids

Walter Gotlieb, MD, PhD

Director, Gynecologic Oncology and Colposcopy, Sir Mortimer B. Davis-Jewish General Hospital
Head, Hereditary Ovarian Cancer Unit, Sir Mortimer B. Davis-Jewish General Hospital
Associate Professor, Departments of Oncology and Obstetrics & Gynecology, McGill University

Medical School
Université Libre de Bruxelles, Brussels, Belgium

Cliniques Universitaires Erasme, U.L.B., Brussels, Belgium

National Cancer Institute, Frederick, MD
UCLA Medical School, Los Angeles, CA            

Clinical Specialties
Gynecologic-Oncology; Surgical Oncology

Research Interests
Molecular biology of cancer; Novel therapeutic modalities; Translational research

Dr. Gotlieb’s research interests focus on ovarian cancer.  Specifically, he is looking at IGF-IR as a target for the treatment of ovarian cancer.  Ovarian cancer is chemoresponsive, but recurrences are common and cures are rare (less than 20%), a new paradigm is needed to shift from response to treatment towards cure. Anti IGF-IR kinase drugs have been shown to enhance apoptosis, and thereby may have an important activity either alone or in combination by enhancing chemotherapy induced cytotoxicity. This work may provide insight into novel combinatorial approaches to ovarian cancer, which could lead to improved therapeutic efficacy and to less toxic dosing schedules. Moreover, this work will provide basic information regarding the expression of proteins of the IGF-IR cascade in sporadic as well as in high risk patients for ovarian cancer, and may reveal potential markers that could predict response to therapy and outcome. Multiple targeting approaches against the IGF-IR including anti-sense nucleotides, antibodies, and dominant negative mutants are being investigated, and may benefit from the information obtained from this research.  The translational aspect of the proposed research might quickly lead to early phase clinical trials.

Walter H. Gotlieb completed his medical degree summa cum laude at the Université Libre de Bruxelles, in his native Belgium, where he went on to obtain board certification in Ob-Gyn.
Following two years at the National Institutes of Health, where he obtained the National Cancer Institute Award of Outstanding Performance, he performed a three year fellowship in Gyn-onc at UCLA. He was then recruited by the by Tel Aviv University, Tel Hashomer Hospital, where he co-founded and built up the Department of Gynaecologic-Oncology from 1994 to 2003.

In 2003, he was recruited by McGill University. He obtained license to practice in Europe, Israel, California, and Canada. In addition to his clinical responsibilities, he is involved in scientific research in ovarian cancer as a Project Director in the Lady Davis Research Institute and Senior Scientist of the Montreal Center for Experimental Therapeutics and Cancer. His efforts focus on translational research and novel therapeutic tools for ovarian cancer, and he has been the pioneer and driven “robotic” surgery in gynaecologic cancer in Canada. He has lectured around the world, and has proctored robotic surgery in Canada, China, India and Israel.

A recipient of twelve national and international awards in the area of cancer research, Dr. Gotlieb is well published with over 90 peer-reviewed manuscripts in reputable international journals. Dr. Gotlieb presently sits on the executive council of the International Gynecologic Cancer Society, and is the secretary treasurer of the Gynecologic Oncology Society of Canada. He is senior editor of the International Journal of Gynecologic Cancer. His prior involvement with medical societies includes the executive council of the Israel Gynecologic Oncologists, the executive council of the Society of Gynecologic Oncologists of Canada, the SGO 2006 program committee, the International Committee of the SGO, and Vice President of the Association des Gynécologues Oncologues du Québec.

Dr. Gotlieb is presently Professor of Ob-Gyn and of Oncology at McGill University. He is the Director of Gynecologic Oncology at the Segal Cancer Center of the Jewish General Hospital, and Director of Surgical Oncology at McGill University.

Additional information on Dr. Walter Gotlieb.